CD34 cell enrichment
Active T cell depletion
Memory T cell enrichment
Isolation of virus-specific T cells
Content
- CD34 cell enrichment
- Active T cell depletion
- Memory T cell enrichment
- Isolation of virus-specific T cells
While HSCT is a well-founded therapeutic option for the treatment of a variety of hematologic malignancies and non-malignant diseases, it is also associated with severe side effects.
We offer a variety of tools that enable the removal of T cells, T cell subsets, B cells, and other unwanted cells from hematopoietic stem cell grafts to potentially overcome relapse and side effects like graft-versus-host diseases.
CD34 cell enrichment
Active T cell depletion
Memory T cell enrichment
Isolation of virus-specific T cells
The CliniMACS® CD34 Reagent System is an FDA-approved method for selecting hematopoietic stem cells from donor apheresis, while passively depleting T cells that can cause graft-versus-host disease (GVHD). Ex vivo T cell depletion can be a viable option to reduce GVHD incidences in patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation.
Active removal of certain T cell subsets from grafts, with the option of concomitant B cell depletion, is a means to reduce the risk of graft-versus-host disease (GVHD) and facilitate engraftment. Dedicated depletion systems on the CliniMACS Plus and CliniMACS Prodigy automate the modification of grafts in closed processing workflows, leaving cells of potential therapeutic benefit in the final product.
Donor-derived memory T cells provide immunologic memory against numerous invaders but are less alloreactive than naive T cells, as demonstrated in allogeneic hematopoietic stem cell transplantation settings. Memory T cell products for clinical use can be manufactured within 4–7 hours in a closed and sterile system using CliniMACS CD45RA Reagents on the CliniMACS Prodigy or CliniMACS Plus Instrument.
Use the CliniMACS Cytokine Capture System (CCS) to easily generate single- and multi-virus specific CD4+ and CD8+ T cells in a highly convenient and fast (within 12 hours) process. The fully integrated and standardized workflow takes place in a closed and sterile system to produce viable antigen-specific T cells that can be used to restore immunity against cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and other infections after hematopoietic stem cell transplantation.
You have previously chosen International as your location.
What do you want to do?